QUANTITY LIMIT CRITERIA

<table>
<thead>
<tr>
<th>DRUG CLASS</th>
<th>5-HT₁ AGONISTS, COMBINATIONS (ALL DOSAGE FORMS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BRAND NAME</td>
<td>ALSUMA (sumatriptan)</td>
</tr>
<tr>
<td></td>
<td>AMERGE (naratriptan)</td>
</tr>
<tr>
<td></td>
<td>AXERT (almotriptan)</td>
</tr>
<tr>
<td></td>
<td>FROVA (frovatriptan)</td>
</tr>
<tr>
<td></td>
<td>Imitrex (sumatriptan)</td>
</tr>
<tr>
<td></td>
<td>MAXALT/ MAXALT-MLT (rizatriptan)</td>
</tr>
<tr>
<td></td>
<td>ONZETRA XSAIL (sumatriptan)</td>
</tr>
<tr>
<td></td>
<td>RELPAX (eletriptan)</td>
</tr>
<tr>
<td></td>
<td>SUMAVEL DosePro (sumatriptan)</td>
</tr>
<tr>
<td></td>
<td>TREXIMET (sumatriptan/naproxen)</td>
</tr>
<tr>
<td></td>
<td>ZEMBRACE SYMTOUCH (sumatriptan)</td>
</tr>
<tr>
<td></td>
<td>ZOMIG / ZOMIG-ZMT (zolmitriptan)</td>
</tr>
</tbody>
</table>

Status: CVS Caremark Criteria
Type: Quantity Limit

Zecuity is not included and clients should implement the Specialty UM if they so desire.

POLICY

FDA-APPROVED INDICATIONS

Alsuma
Alsuma (sumatriptan injection) is indicated in adults for the acute treatment of migraine, with or without aura, and the acute treatment of cluster headache.
Use only if a clear diagnosis of migraine or cluster headache has been established. If a patient has no response to the first migraine attack treated with Alsuma, reconsider the diagnosis of migraine before Alsuma is administered to treat any subsequent attacks.
Alsuma is not indicated for the prevention of migraine attacks.

Amerge
Amerge tablets are indicated for the acute treatment of migraine attacks with or without aura in adults.
Amerge tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar. Safety and effectiveness of Amerge tablets have not been established for cluster headache, which is present in an older, predominantly male population.

Axert
Adults: Axert (almotriptan malate) is indicated for the acute treatment of migraine attacks in patients with a history of migraine with or without aura.
Adolescents Age 12 to 17 Years: Axert is indicated for the acute treatment of migraine headache pain in patients with a history of migraine attacks with or without aura usually lasting 4 hours or more (when untreated).
Axert should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with Axert, the diagnosis of migraine should be reconsidered before Axert is administered to treat any subsequent attacks.
In adolescents age 12 to 17 years, efficacy of Axert on migraine-associated symptoms (nausea, photophobia, and phonophobia) was not established. Axert is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine.
Safety and effectiveness of Axert have not been established for cluster headache which is present in an older, predominantly male population.

Frova
Frova tablets are indicated for the acute treatment of migraine attacks with or without aura in adults.
Frova is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. The safety and effectiveness of Frova have not been established for cluster headache, which is present in an older, predominantly male, population.

**Imitrex Injection**

Imitrex Injection is indicated for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache episodes.

Use only if a clear diagnosis of migraine or cluster headache has been established. If a patient has no response to the first migraine attack treated with Imitrex, reconsider the diagnosis of migraine before Imitrex is administered to treat any subsequent attacks. Imitrex is not indicated for the prevention of migraine attacks.

**Imitrex Nasal Spray and Imitrex Tablets**

Imitrex Nasal Spray and Imitrex Tablets are indicated for the acute treatment of migraine attacks with or without aura in adults.

Imitrex Nasal Spray and Tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Safety and effectiveness of Imitrex Nasal Spray and Tablets have not been established for cluster headache, which is present in an older, predominantly male population.

**Maxalt-MLT and Maxalt Tablets**

Maxalt-MLT and Maxalt Tablets are indicated for the acute treatment of migraine attacks with or without aura in adults.

Maxalt should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with Maxalt, the diagnosis of migraine should be reconsidered before Maxalt is administered to treat any subsequent attacks. Maxalt is not indicated for use in the management of hemiplegic or basilar migraine. Maxalt is not indicated for the prevention of migraine attacks. Safety and effectiveness of Maxalt have not been established for cluster headache.

**Onzeta Xsail**

Onzeta Xsail is indicated for the acute treatment of migraine with or without aura in adults.

Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with Onzeta Xsail, reconsider the diagnosis of migraine before treatment of subsequent attacks with Onzeta Xsail.

Onzeta Xsail is not indicated for the prevention of migraine attacks. Safety and effectiveness of Onzeta Xsail have not been established for the treatment of cluster headache.

**Relpax**

Relpax tablets are indicated for the acute treatment of migraine attacks with or without aura in adults.

Relpax is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Safety and effectiveness of Relpax Tablets have not been established for cluster headache, which is present in an older, predominantly male population.

**Sumavel DosePro**

Sumavel DosePro is indicated in adults for (1) the acute treatment of migraine, with or without aura, and (2) the acute treatment of cluster headache.

Use only if a clear diagnosis of migraine or cluster headache has been established.

If a patient has no response to the first migraine attack treated with Sumavel DosePro, reconsider the diagnosis of migraine before Sumavel DosePro is administered to treat any subsequent attacks.

Sumavel DosePro is not indicated for the prevention of migraine attacks.

**Treximet**

Treximet is indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years of age and older.

Use only if a clear diagnosis of migraine headache has been established. If a patient has no response to the first migraine attack treated with Treximet, reconsider the diagnosis of migraine before Treximet is administered to treat any subsequent attacks.

Treximet is not indicated for the prevention of migraine attacks. Safety and effectiveness of Treximet have not been established for cluster headache.

**Zembrace SymTouch**

Zembrace SymTouch is indicated for the acute treatment of migraine with or without aura in adults.

Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with Zembrace SymTouch, reconsider the diagnosis before Zembrace SymTouch is administered to treat any subsequent attacks.

Zembrace SymTouch injection is not indicated for the prevention of migraine attacks.

**Zomig Nasal Spray, Tablets, and Zomig-ZMT**

Zomig is indicated for the acute treatment of migraine with or without aura in adults.
Zomig should only be used if a clear diagnosis of migraine has been established. If a patient has no response to Zomig treatment for the first migraine attack, reconsider the diagnosis of migraine before Zomig is administered to treat any subsequent attacks. Zomig is not indicated for the prevention of migraine attacks. Safety and effectiveness of Zomig have not been established for cluster headache. Zomig nasal spray is not recommended in patients with moderate or severe hepatic impairment.

REFERENCES
### LIMIT CRITERIA

The intent is for the patient to receive only one drug from this drug class at a time.

PLEASE NOTE: Since manufacturer package sizes may vary, it is the discretion of the dispensing pharmacy to fill quantities per package size up to these quantity limits. In such cases the filling limit and day supply may be less than what is indicated.

Zecuity is not included and clients should implement the Specialty UM if they so desire.

**PEACE NOTE:** Since manufacturer package sizes may vary, it is the discretion of the dispensing pharmacy to fill quantities per package size up to these quantity limits. In such cases the filling limit and day supply may be less than what is indicated.

The intent is for the patient to receive only one drug from this drug class at a time.

### Medication

<table>
<thead>
<tr>
<th>Medication</th>
<th>Strength</th>
<th>Dose per head</th>
<th>Maximum dose per 24 hours</th>
<th>Package Size</th>
<th>1 Month Limit *</th>
<th>3 Months Limit *</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alsuma (sumatriptan)</td>
<td>6 mg</td>
<td>1-2 injections</td>
<td>2 injections 12 mg</td>
<td>2 autoinjectors 0.5mL each</td>
<td>12 injectors / 25 days</td>
<td>36 injectors / 75 days</td>
</tr>
<tr>
<td>Amerge (naratriptan)</td>
<td>1 mg</td>
<td>1-2 tablets</td>
<td>2 tablets</td>
<td></td>
<td>12 tablets / 25 days</td>
<td>36 tablets / 75 days</td>
</tr>
<tr>
<td>Axert (alimotriptan)</td>
<td>6.25 mg</td>
<td>1-2 tablets</td>
<td>2 tablets</td>
<td>6 tablets</td>
<td>12 tablets / 25 days</td>
<td>36 tablets / 75 days</td>
</tr>
<tr>
<td>Frova (frovatriptan)</td>
<td>2.5 mg</td>
<td>1-2 tablets</td>
<td>3 tablets 7.5 mg</td>
<td>9 tablets</td>
<td>18 tablets / 25 days</td>
<td>54 tablets / 75 days</td>
</tr>
<tr>
<td>Imitrex Injection (sumatriptan) vials</td>
<td>6 mg</td>
<td>1-2 injections</td>
<td>2 injections 12 mg</td>
<td>5 single dose vials 0.5mL each</td>
<td>12 vials / 25 days</td>
<td>40 vials / 75 days</td>
</tr>
<tr>
<td>Imitrex Injection (sumatriptan) syringes</td>
<td>4 mg</td>
<td>1-2 injections</td>
<td>3 injections 12 mg</td>
<td>18 syringes / 25 days</td>
<td>54 syringes / 75 days</td>
<td>36 syringes / 75 days</td>
</tr>
<tr>
<td>Imitrex Nasal Spray (sumatriptan)</td>
<td>5 mg</td>
<td>1-4 sprays</td>
<td>4 sprays</td>
<td>6 nasal spray units</td>
<td>24 units / 25 days</td>
<td>72 units / 75 days</td>
</tr>
<tr>
<td>Imitrex Tablets (sumatriptan)</td>
<td>25mg, 50mg</td>
<td>1-2 tablets</td>
<td>2 tablets</td>
<td>12 tablets / 25 days</td>
<td>36 tablets / 75 days</td>
<td></td>
</tr>
<tr>
<td>Maxalt / Maxalt-MLT (rizatriptan)</td>
<td>5 mg</td>
<td>1-2 tablets</td>
<td>3 tablets</td>
<td>12 tablets / 25 days</td>
<td>18 tablets / 25 days</td>
<td>54 tablets / 75 days</td>
</tr>
<tr>
<td>Onzetra XsaiIl (sumatriptan)</td>
<td>11mg</td>
<td>2 nosepieces</td>
<td>4 nosepieces 44mg</td>
<td>8 pouches per kit 2 nosepieces per pouch</td>
<td>1 kit / 25 days (8 pouches, 16 nosepieces)</td>
<td>3 kits / 75 days (24 pouches, 48 nosepieces)</td>
</tr>
<tr>
<td>Relpx (eletriptan)</td>
<td>20 mg</td>
<td>1-2 tablets</td>
<td>2 tablets</td>
<td>6 tablets</td>
<td>12 tablets / 25 days</td>
<td>36 tablets / 75 days</td>
</tr>
<tr>
<td>Sumavel DosePro (sumatriptan)</td>
<td>4 mg</td>
<td>1-2 injections</td>
<td>3 injections 12 mg</td>
<td>18 injections / 25 days</td>
<td>54 injections / 75 days</td>
<td>36 injections / 75 days</td>
</tr>
<tr>
<td>Treximet (sumatriptan/naproxen)</td>
<td>10mg/60mg</td>
<td>1 tablet</td>
<td>1 tablet</td>
<td>9 tablets / 25 days</td>
<td>18 tablets / 75 days</td>
<td>36 tablets / 75 days</td>
</tr>
<tr>
<td>Zembrace SymTouch (sumatriptan)</td>
<td>3 mg</td>
<td>1-4 injections</td>
<td>4 injections 12mg</td>
<td>4 autoinjectors 0.5mL each</td>
<td>24 injectors / 25 days</td>
<td>72 injectors / 75 days</td>
</tr>
<tr>
<td>Zomig / Zomig-ZMT (zolmitriptan)</td>
<td>2.5 mg</td>
<td>1/2-2 tablets</td>
<td>2 tablets</td>
<td>6 tablets</td>
<td>12 tablets / 25 days</td>
<td>36 tablets / 75 days</td>
</tr>
<tr>
<td>Zomig Nasal Spray (zolmitriptan)</td>
<td>2.5 mg</td>
<td>1-2 sprays</td>
<td>2 sprays</td>
<td>6 nasal spray units</td>
<td>12 tablets / 25 days</td>
<td>36 tablets / 75 days</td>
</tr>
</tbody>
</table>

* The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing.